Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fluzone Quadrivalent

Sanofi reception

Sanofi and Lexicon collaborate on new medication for diabetes

Plan to develop new investigational drugsotagliflozin

Sanofi reception

Sanofi and Hanmi collaborate on diabetes treatments

Aims to optimise efficacy of medications

Sanofi reception

Sanofi forges $1.5bn cancer partnership with BioNTech

Set to develop five cancer therapies

- PMLiVE

Sanofi posts positive data for MS drug Aubagio

Phase III study shows drug slows brain volume loss

- PMLiVE

Express Scripts ‘will pay $750m on PCSK9 inhibitors next year’

Amgen's Repatha and Sanofi's Praluent included

- PMLiVE

Genzyme opts into gene silencing therapy for haemophilia

Interim results show positive benefits for ALN-AT3

Sanofi reception

Sanofi’s lixisenatide is back under FDA review

Brings GLP-1 agonist closer to US market

Eli Lilly HQ

Lilly set to launch Lantus biosimilar in the US next year

Settlement ends the company's legal dispute with Sanofi

- PMLiVE

New data arms Novo Nordisk for insulin battle with Sanofi

Tresibaand Xultophy boosted by studies presented at EASD 

Sanofi reception

Sanofi plans LixiLan filings after positive phase III trial

Combination drug could cause dynamic shift in diabetes treament

Sanofi and Google partner on digital health in diabetes

Aimto develop new patient tools by harnessing data and miniaturised tech

Sanofi reception

Sanofi and Evotec to work together on diabetes and cancer

Willfocus on beta cell-modulating diabetes treatments and immuno-oncology therapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links